PharmaJet and Abnova to Jointly Develop and Deliver COVID-19 mRNA Vaccine Using Needle-Free Injection Technology
By HospiMedica International staff writers Posted on 20 May 2020 |
Image: The PharmaJet Stratis Needle-Free Injector (Photo courtesy of PharmaJet)
PharmaJet’s (Golden, CO, USA) Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2 that is being developed by Abnova Corporation (Taipei, Taiwan).
Abnova's DNAx Immune technology enables the rapid production of highly sensitive and specific antibodies for research, in vitro diagnostics, and therapeutic antibody applications. By leveraging the DNAx gene sequence antibody response bioinformatics, Abnova is accelerating the development of mRNA vaccines targeting infectious diseases and cancers. It has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of its mRNA candidate.
"We have taken a major next step toward mRNA vaccine development against COVID-19 based on the specific gene sequences generating successful antibody response from our DNAx Immune platform," said Dr. Wilber Huang, President and CEO, Abnova. "We would like to complement the mRNA immunization with a needle-free platform to further augment the protective antibody response against COVID-19 with an impactful clinical outcome."
"We are pleased to be collaborating with Abnova on the development of their SARS-CoV-2 mRNA vaccine," commented Chris Cappello, President and CEO, PharmaJet, "Our system has been found to improve the immune response of multiple RNA/DNA vaccines, in addition to its proven ease of administration in wide-scale immunization settings."
Related Links:
PharmaJet
Abnova
Abnova's DNAx Immune technology enables the rapid production of highly sensitive and specific antibodies for research, in vitro diagnostics, and therapeutic antibody applications. By leveraging the DNAx gene sequence antibody response bioinformatics, Abnova is accelerating the development of mRNA vaccines targeting infectious diseases and cancers. It has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of its mRNA candidate.
"We have taken a major next step toward mRNA vaccine development against COVID-19 based on the specific gene sequences generating successful antibody response from our DNAx Immune platform," said Dr. Wilber Huang, President and CEO, Abnova. "We would like to complement the mRNA immunization with a needle-free platform to further augment the protective antibody response against COVID-19 with an impactful clinical outcome."
"We are pleased to be collaborating with Abnova on the development of their SARS-CoV-2 mRNA vaccine," commented Chris Cappello, President and CEO, PharmaJet, "Our system has been found to improve the immune response of multiple RNA/DNA vaccines, in addition to its proven ease of administration in wide-scale immunization settings."
Related Links:
PharmaJet
Abnova
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans